Dose-response data for GH-releasing peptides are limited. We studied the effects of varying doses (O-l.0
(J Clin Endocrinol Metab 81: [4338] [4339] [4340] [4341] 1996) H EXARELIN (His-o-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH,) is a novel GH-releasing peptide (GHRP) capable of massive GH secretion after iv, SC, intranasal, and oral administration and is well tolerated in man (1, 2). It is an analog of GHRP-6 in which the D-tryptophan has been substituted for its 2-methyl derivative.
The GH-releasing activity of hexarelin and other GHRPs has been extensively studied in both health and disease states (2-S). The high potency and low toxicity of these peptides together with their oral activity have made them likely candidates for future therapeutic uses in GH deficiency states.
Most studies of GHRPs have been conducted using 1 .O pg peptide/ kg BW, given iv, a dose capable of generating high serum GH concentrations (2) (3) (4) (5) (9) (10) (11) (12) (13) 
Study design
After an overnight fast, subjects were admitted to the clinical unit and remained in a recumbent position throughout the study session. Two indwelling iv cannulas were inserted in the forearms at 0830 h (-60 min). One cannula was used for drug administration, and the other for collection of blood specimens.
Blood samples for measurement of serum GH, PRL, cortisol, TSH, insulin, and blood glucose were drawn at 15-min intervals from 0900 h (~30) to 1130 h (120 min). At 0930 h (0 min), a bolus of saline, The PRL dose-response curve is shown in Fig. 3 . The curve reached a plateau at approximately 180%. The maximum percent rise in the PRL concentration from baseline values at 0 min corresponds to a hexarelin dose of 1.0 kg/ kg. The ED,, was 0.39 2 0.02 pg/kg (mean -C SEM). The best-fit curve for the maximum change in PRL concentration for all subjects was described by the cubic equation: y = 25.6 -160.6 (hexarelin dose) + 1291.9 (hexarelin dose? -1005.5 (hexarelin dose)", where y is the serum PRL concentration.
Cortisol dose-response curve Serum cortisol concentrations were measured using a solid phase RIA (Coat-A-Count, Diagnostic Products Corp., Los Angeles, CA). The sensitivity of the assay was 5.5 nmol/L. Intraassay coefficients of variation were 5.7%, 3.1% and 2.6% at serum cortisol concentrations of 27.6, 96, and 552 nmol/L, respectively; interassay coefficients of variation were 6.3% and 4.5% at concentrations of 138 and 276 nmol/ L, respectively.
The dot plot of increasing doses of iv hexarelin us. the maximum percent change in serum cortisol concentration compared to baseline values at 0 min (Fig. 4) dose-response effect. The maximum percent changes in the serum cortisol concentration after the iv administration of low doses of hexarelin (~0.375 pg/ kg) were equally distributed around the zero line, with no clear-cut rise or fall in concentration, although the median values were slightly positive. However, at higher doses (20.5 pg/ kg) the change was predominantly an increase. The data could be described as a step change to a new plateau of maximum percent change in serum cortisol concentration.
An approximate 40% step change occurred at a hexarelin dose of 0.5 pg/kg. 
GHRH and combined GHRH and hexarelin studies
The peak serum GH responses to GHRH-(l-29)-NH, (1.0 pg/ kg), hexarelin (0.125 pg/ kg), and GHRH-(I-29)-NH, (1.0 pg/kg) with hexarelin (0.125 Fg/kg) were 42.5 5 7.8, 7.9 -C 4.1, and 115 2 32.8 mu/L, respectively. The corresponding maximum percent changes in serum PRL concentrations were 72.0 t-23.3%' 28.5 + 17.8%, and 84.9 2 27.5%, respectively. There was no rise in serum cortisol concentration after the administration of GHRH-(l-29)-NH, (1.0 pg/ kg) alone or in combination with low dose hexarelin (0.125 pg/kg), and there was only a small rise after low dose hexarelin (0.125 pg/kg) alone (mean ? SEM, 7.6 + 21.2%).
Discussion
This study shows that iv hexarelin is capable of inducing GH release in a dose-dependent manner in healthy adult males and that hexarelin is a nonspecific GH secretagogue, inducing concomitant increases in serum PRL and cortisol levels. The rise in serum PRL was dose related, whereas that in cortisol occurred beyond a threshold dose of hexarelin. Intravenous hexarelin had no effect on blood sugar, serum insulin, or serum TSH concentrations.
The combined iv administration of GHRH-(I-29)-NH, with low dose hexarelin restored its massive GH-releasing ability and resulted in only a modest elevation of PRL levels, with no effect on cortisol secretion.
Most studies of hexarelin have been conducted using high doses (1.0 pg/kg), which are known to induce massive GH release. Such levels are not needed for normal linear growth. Doses of hexarelin capable of generating lower, but adequate, levels of GH in the blood are more likely to be used in therapy because they would mimic the physiological levels of serum GH essential for normal growth. Our data show that doses of hexarelin as low as 0.2 pg/kg are capable of generating serum GH concentrations equivalent to the maximum seen in normal adults during the day (21, 22) and would be expected to generate at least similar levels in children.
The GH dose-response curve showed a plateau at a dose of 1.0 pg/ kg, suggesting that such a dose was near-maximal. A dose response study by Imbimbo et al. (19) in which up to 2.0 pg/ kg were administered to normal adults showed that increasing the dose of hexarelin from 1 to 2 pg/ kg resulted in only an additional 6% increase in the serum GH concentration, suggesting that the maximal GH response to hexarelin occurred between l-2 pg/kg. Establishing the maximal and near-maximal doses of hexarelin is important because it may have a role as a diagnostic test (23), and the level is useful for comparison with other tests of pituitary GH reserve, such as the GHRH test, in which the use of maximal to supramaximal doses is standard practice for testing the readily available pool of GH (24).
The concomitant increases in serum PRL and cortisol after treatment with iv hexarelin indicates, contrary to earlier beliefs (17, 25) , that GHRPs are not as specific GH secretagogues as was first thought. The absence of a hexarelin effect on serum TSH levels argues against the effect on PRL being TRH mediated.
Besser et al. (26) document&d this nonspecificity of hexarelin and found that the cortisol release was accompanied by a rise in ACTH. These data suggest that hexarelin acts at receptor sites not purely confined to the somatotroph. Although the maximum levels to which serum PRL and cortisol concentrations rose remained within the normal range, and the values returned to baseline levels by 120 min, these findings may have far reaching implications in terms of the potential use of GHRPs in the therapeutic setting. The prolonged and repeated use of GHRPs may result in hypercortisolemic and/or hyperprolactinemic states if such effects on PRL and cortisol release are sustained. Our study has only addressed these effects in the acute setting, so the effects of chronic administration of hexarelin on serum PRL and cortisol remain unknown.
It is prudent to mention that to date there have been no reports of orally administered GHRPs resulting in significant PRL release (27, 28). The reasons for this are unclear, but may be related to its bioavailability after oral ingestion. The finding that the hexarelin-induced rise in serum PRL and cortisol is dose dependent, coupled with its dosedependent GH release, has enabled us to identify a dose of hexarelin (0.2 pg/kg) that results in adequate GH release with minimal effect on serum cortisol and PRL. The synergistic GH-releasing effect of GHRH and GHRPs, using near-maximal doses, is well documented (27). The use of low dose GHRP with a maximal dose of GHRH is also known to be synergistic (27). Our study shows that the combination of GHRH and low dose hexarelin induces massive GH release with no effect on serum cortisol and only a modest elevation of serum PRL levels. Furthermore, using a combination of GHRH and low dose hexarelin restored and exceeded the massive GH release observed with hexarelin alone. This opens up the possibility of using even smaller doses of GHRP in combination with GHRH. The obvious route of GHRP administration would be oral, given perhaps twice daily, with GHRH given as a depot preparation.
This study provides important dose-response data for hexarelin's GH-, PRL-, and cortisol-releasing properties. It provides further confirmation of the synergistic action of low dose GHRP and GHRH and the potential advantage of applying this approach in future trials. 
